Introduction
After sulphonylurea therapy had been used for a short time, oral tolbutamide-response tests for predicting results of long-term treatment were suggested * Support of this Study by Deutsche Forsehungsgemeinschaft (Pf 38/28) is gratefully acknowledged. in 1957 by Pfeiffer et al. [15] and Camerini-DavMos et al. [1] . Blood sugar decreases of more than 30% of the initial values were taken as indicating favourable responses to long-term tolbutamide treatment. Later, i. v. r tests were suggested for differentiating normal subjects from latent or chemical diabetes [11, Diabetologla 18] or for recognizing hypoglycaemia due to insulinoma [4, 6, 14] .
After the criteria for oral antidiabetic therapy were firmly established there was no further need for prediction tests. However, the new drug glibenclamide was tried not only in patients with secondary response failures to tolbutamide or other oral drugs [16, 17] , but Mso in an increasing percentage of rather severe elderly diabetics with clear-cut insnlin-dependence [9] .
Experimental Concept and Technical Approach
Again, the question of selection criteria arose, i.e. whether or not prediction of the outcome of long-term therapy with glibenclamide was possible. Combined intravenous administration of glibenclamide plus glucose was preferred to glibenclamide injection alone to provide maximum stimulation of the releasable pancreatic insulin reserves. As published elsewhere [5, 13, 16] , isolated Langerhans' islets and the isolated perfused rat pancreas as well as normal human beings responded to the combined action of glibenclamideglucose, even under repeated administration, with higher insulin releases than to the combined tolbutamide-glucose injection or to glucose, tolbutamide or glibenclamide alone. In addition, those patients with secondary failures of tolbutamide therapy responded to glibenclamide plus glucose with more vigorous insulin secretions than to glibenclamide alone [12, 16] .
Unfortunately, in the more severe cases treated with insulin for extended periods of time evaluation of blood glucose levels after stimulation with glibenclamide plus glucose became somewhat difficult. This applied particularly to those patients who, according to the established rules, were not regarded as suitable cases for orM antidiabetic therapy. The low glucose disappearance rates (K-values) were not markedly influenced by either glibenclamide or glibenclamide plus glucose. This suggested the necessity of measuring and comparing the concentrations of immunologically measurable insulin (IMI) concentrations in serum before and after injection of glibenclamide plus glucose.
However, it had to be considered that extended periods of treatment with exogenous insulin (at least 40 U of long acting insnlin/day, sometimes more than 100 U/day) had induced some kind of immunological insulin resistance in the majority of those cases where insulin-binding capacities in serum were increased.
Hence, treatment of serum prior to insulin measurement was carried out according to Heding [7] : the antibodies were separated from the antigen by serum acidification followed by alcohol precipitation in alkali solution. If some exogenous insulin was still contributing to the IMI-vMues measured, neglecting it seemed justified. After all it was only the increase, particularly the individual increase, in endogenous hormone which accounted for the increment following stimulation.
Patients and Methods
Forty 43--75 year old insulin-dependent subjects with diabetic conditions of up to 21 years duration were submitted to identical response tests. They were then transferred from insulin to glibenclamide in doses of 5--15 mg, remaining in hospital under constant observation. Severe retinopathy with impairment of visual function made the change from insulin to tablets advisable in a number of these diabetics. 29 of the 40 patients did not respond to long-term glibenclamide therapy and had to be changed back to insulin after two or three days. In. this connection "excellent" means that the blood sugar amounted to less than 160 rag% and a glucose excretion of less than 2 g during the 24 h period; "good" means blood sugar values lower than 180 rag% and a glucose excretion of less than 7 g during the 24 h period; whereas the term "failure" marks rises in blood sugar values above 200 rag% and a glucose excretion exceeding 10g during the 24h period.
In order to demonstrate once more the enormous differences between the amounts of insulin released in normal and diabetic subjects following stimulation, as well as the time differences between peak increments in blood insulin in normals and diabetics following tolbutamide and glibenclamide administration, twelve normal individuals were included. Each of the subjects was tested on five consecutive days, which were sometimes interrupted by an interval of two days during which exogenous insulin was given again, with i.v. glucose loads (0.33 g/kg) to establish the basic response in absolute insulin concentrations per ml, the percentage of the individual increases and the time periods at which the maximum rise in insulin was recorded; to i.v. tolbutamide 1 (25 mg/kg) and tolbutamide-k glucose (25 mg Jr 0.33 g/kg) as well as to i.v. glibenclamide (25 9g/kg) and glibenclamide i -+-glucose (25 ~g-k 0.33 g/kg) loads. The stimulatory substances were slowly injected over a period of 2 rain. Venous blood samples for determination of blood glucose and insulin were secured at 5, 10, 20, 30, 40, 50, 60, 90, 120, 150 and 180 rain following injection. The fasting patients were examined between 8 and 9 a.m. 36 h after withdrawal of exogenous insulin blood sugar was determined according to Hoffmann [8] by autoanalyzer. The blood was centrifuged at low temperatures and the serum separated and stored in the deep-freeze at --30~ After pretreatment of serum [7] , insulin was determined according to Melani et al. [10] by separating free and bound insulin by means of amberlite (CG 400 type II). Glucose disappearance rates were calculated according to Conard [19] in the normal subjects and according to Dost [2, 3] in the diabetics. Table 3 . b Of highest peak of serum insulin recorded during test.
Changes in serum insulin induced by glucose and sulphonylureas i.v. in normal subjects

Clinical data and changes in serum insulin induced by glucose and sulphonylureas i.v. in 12 insulin-dependent diabetics; responding satisfactorily to long-term treatment with glibenclamide
Results
As shown in Table 1 , glucose as well as tolbutamide acted much faster than glibenclamide in fifteen normal subjects on insulin release, but the effect of glibenclamide plus glucose combined quantitatively exceeded all others.
The clinical and laboratory findings in an arbitrary selection of 12 out of 29 subjects with primary failures
The group of patients successfully treated with glibenclamide for up to 7 and 8 months following the response tests (until November 1971 more than 18 months) did not differ clinically from those who did not respond to 10hi-term treatment. The insulin responses to glucose and tolbutamide or glibenclamide alone were not very different from those seen in nonresponsive subjects (Table 3 ).
In addition, the effect of tolbutamide plus glucose Table 2 . The responses to glucose and tolbutamide as well as to tolbutamide plus glucose were very modest, and glibenclamide alone also did not effect remarkable rises in plasma insulin. The average increases following glibenclamide plus glucose amounted to only 20.8 ~ 2.4 ~U/ml, i.e. 291.8 -t-33.43 mean percentage increment above the initial levels. It should be noted that the insulin peaks following tolbutamide and glibenclamide, respectively, occur at different time periods.
was not greater in the responsive as against the nonresponsive subjects. Glibenclamide plus glucose, however, induced average insulin increases of 47.6 -4-2.1 ~U/ ml, i.e. 665.8 :E 54.7 mean percentage increment above initial values. The differences in the percentage increases in the three groups following glucose, glucose plus tolbutamide and glucose plus glibenclamide, respectively, are illustrated in Fig. 1 . A positive reaction to the glibenclamide-F glucose load contrasted with a primary response failure ap-pearing 10 days after initiation of oral treatment in only one case (S.J. Table 3 ).
The average increases in absolute insulin concentrations and in mean percentage increment (above initiM values) for all three groups in response to the five stimulants are summarized in Table 4 .
Conclusions
From these results it was inferred: 1. that the "Glibenclamide-Glucose-l~esponse-Test" may be helpful in predicting the outcome of longterm glibenclamide treatment, even in more severe elderly diabetics who were previously considered to be insulin-dependent and non-responsive to sulphonylureas; 2. that the correlation between the positive Glibenclamide-Glucose-Response-Test (i.e. mean percentage insulin increases of more than 500% above initial values) and successful long-term treatment favours the hypothesis that a continuous stimulation of endogenous insulin secretion is the predominant mechanism of action of the new compound following both single and permanent application; 3. that, surprisingly enough, the relation between the absolute amounts of insulin released in response to the various stimuli is between the normal subjects and the diabetics (the positive responders) in the same order of about 5 : 1 ; 4. that, therefore, the synergistic action or potentiation of glibenclamide and glucose and vice versa suggests an action on the receptor site of the fl-eell in both the normal and the diabetic subjects, and no particular action of the new drug on the diabetic fl-cells alone; 5. that the proportion of elderly diabetics formerly considered to be "purely" or "truly" insulin dependent, i.e. diabetic subjects unable to synthesize even minute amounts of insulin, is much less than was held before; 6. that a practical advantage of glibenclamide over insulin therapy in this type of patient should prove to be the case in subjects suffering from severe retinopathy or other ocular complications inducing impairment of visual function and incapacity to inject oneself. Further mathematical analysis of the blood glucose changes induced by the various stimulations will show whether or not a simple formula exists which would permit rapid evaluation of the Glibenclamide-Glucosel~esponse-Test without ha~ng to rely upon serum insulin determinations.
